Identification

Name
Calcium Acetate
Accession Number
DB00258  (APRD00839)
Type
Small Molecule
Groups
Approved, Investigational
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]

Structure
Thumb
Synonyms
  • Acetate OF lime
  • Brown acetate of lime
  • Ca(oac)2
  • calcium ethanoate
  • calcium(II) acetate
  • Gray acetate of lime
  • Lime acetate
  • Lime pyrolignite
External IDs
E-263 / FEMA NO. 2228 / INS NO.263 / INS-263
Product Ingredients
IngredientUNIICASInChI Key
Calcium acetate monohydrate7ZA48GIM5H5743-26-0XQKKWWCELHKGKB-UHFFFAOYSA-L
Active Moieties
NameKindUNIICASInChI Key
CalciumprodrugSY7Q814VUP7440-70-2OYPRJOBELJOOCE-UHFFFAOYSA-N
Acetate ionionic569DQM74SC71-50-1QTBSBXVTEAMEQO-UHFFFAOYSA-M
Calcium cationionic2M83C4R6ZB14127-61-8BHPQYMZQTOCNFJ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PhosloCapsule667 mg/1OralPhysicians Total Care, Inc.1997-08-272006-10-11Us54868 346020180907 15195 1ynv54e
PhosloCapsule667 mg/1OralPhysicians Total Care, Inc.2010-03-01Not applicableUs49230 0640 21 nlmimage10 c81c6413
PhosLoCapsule667 mg/1OralFresenius Medical Care North America2001-04-02Not applicableUs
PhosloCapsule667 mg/1OralCardinal Health2001-04-02Not applicableUs55154 775020180907 15195 us3wbw
Phoslo TabletsTablet667 mgOralFresenius Medical Care North America2006-02-222013-07-29Canada
PhoslyraSolution667 mg/5mLOralFresenius Medical Care North America2011-04-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium AcetateCapsule667 mg/1OralMc Kesson Contract Packaging2008-02-262017-09-30Us
Calcium AcetateCapsule667 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-02-26Not applicableUs
Calcium AcetateTablet667 mg/1OralCamber Pharmaceuticals2014-02-03Not applicableUs
Calcium AcetateCapsule667 mg/1OralCardinal Health2008-02-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Calcium AcetateCapsule667 mg/1OralSandoz2012-03-14Not applicableUs
Calcium AcetateCapsule667 mg/1OralRemedy Repack2010-11-112011-11-12Us
Calcium AcetateCapsule667 mg/1OralEci Pharmaceuticals Llc2017-02-25Not applicableUs
Calcium AcetateCapsule667 mg/1OralCardinal Health2013-07-26Not applicableUs
Calcium AcetateCapsule667 mg/1OralMarlex Pharmaceuticals Inc2017-05-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetate Tab 667mgTablet667 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1993-12-312002-07-31Canada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aluminum Acetate AstringentCalcium Acetate (839 mg/2030mg) + Aluminum sulfate hydrate (1191 mg/2030mg)Powder, for solutionTopicalTagi Pharma Incorporated2011-06-15Not applicableUs
Aluminum Acetate AstringentCalcium Acetate (839 mg/2030mg) + Aluminum sulfate hydrate (1191 mg/2030mg)Powder, for solutionTopicalEpic Pharma, LLC2011-02-282013-04-30Us
AstringentCalcium acetate monohydrate (952 mg/2299mg) + Aluminum sulfate tetradecahydrate (1347 mg/2299mg)Powder, for solutionTopicalTAGI Pharma, Inc.2012-06-01Not applicableUs
DomeboroCalcium acetate monohydrate (952 mg/1) + Aluminum sulfate tetradecahydrate (1347 mg/1)Powder, for solutionTopicalMOBERG PHARMA NORTH AMERICA LLC2012-06-26Not applicableUs
Hyperlyte (multi-electrolyte Concentrate)Calcium Acetate (440 mg) + Sodium gluconate (1.09 g) + Magnesium acetate (860 mg) + Potassium Chloride (2.46 g) + Potassium acetate (690 mg) + Sodium acetate (2.72 g)LiquidIntravenousB. Braun Medical Inc.1998-09-04Not applicableCanada
LypholyteCalcium Acetate (440 mg) + Sodium gluconate (1.1 g) + Magnesium acetate (860 mg) + Potassium Chloride (2.5 g) + Potassium acetate (690 mg) + Sodium acetate (2.7 g)SolutionIntravenousPartners Health Care, Inc.1996-08-142008-01-10Canada
Lypholyte Multi-electrolyte Conc InjCalcium Acetate (22 mg) + Sodium gluconate (55 mg) + Magnesium acetate (43 mg) + Potassium Chloride (125 mg) + Potassium acetate (34.5 mg) + Sodium acetate (135 mg)LiquidIntravenousLyphomed, Division Of Fujisawa Canada Inc.1991-12-311996-09-10Canada
ProcalAmineCalcium Acetate (0.026 g/100mL) + Glycerin (3 g/100mL) + Glycine (0.42 g/100mL) + Histidine (0.085 g/100mL) + L-Alanine (0.21 g/100mL) + L-Arginine (0.29 g/100mL) + L-Cysteine hydrochloride (0.014 g/100mL) + L-Isoleucine (0.21 g/100mL) + L-Leucine (0.27 g/100mL) + L-Lysine acetate (0.22 g/100mL) + L-Phenylalanine (0.17 g/100mL) + L-Proline (0.34 g/100mL) + L-Threonine (0.12 g/100mL) + L-Tryptophan (0.046 g/100mL) + L-Valine (0.2 g/100mL) + Magnesium acetate (0.054 g/100mL) + Methionine (0.16 g/100mL) + Phosphoric acid (0.041 g/100mL) + Potassium Chloride (0.15 g/100mL) + Serine (0.18 g/100mL) + Sodium Chloride (0.12 g/100mL) + Sodium acetate trihydrate (0.2 g/100mL)InjectionIntravenousB. Braun Medical Inc.1982-05-06Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
NutrilyteCalcium Acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium Chloride (125 mg/1mL) + Potassium acetate (34.5 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL)Injection, solution, concentrateIntravenousAmerican Regent1990-09-302013-05-08Us
PhosloCalcium Acetate (667 mg/1)CapsuleOralNabi Biopharmaceuticals2007-01-01Not applicableUs
PhosloCalcium Acetate (667 mg/1)TabletOralNabi Biopharmaceuticals2007-01-01Not applicableUs
International/Other Brands
Teltozan
Categories
UNII
Y882YXF34X
CAS number
62-54-4
Weight
Average: 158.166
Monoisotopic: 157.989199835
Chemical Formula
C4H6CaO4
InChI Key
VSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O

Pharmacology

Indication

Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.

Associated Conditions
Pharmacodynamics

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Mechanism of action

Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.

TargetActionsOrganism
APhosphate
binder
Human
Absorption

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.

Half life
Not Available
Clearance
Not Available
Toxicity

Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1alpha-Hydroxyvitamin D5The risk or severity of adverse effects can be increased when Calcium Acetate is combined with 1alpha-Hydroxyvitamin D5.
3-Aza-2,3-Dihydrogeranyl DiphosphateCalcium Acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetyldigitoxinCalcium Acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
AcetyldigoxinCalcium Acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium Acetate.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Acetate.
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Acetate is combined with Alfacalcidol.
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Acetate.
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Acetate.
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Acetate.
Food Interactions
Not Available

References

Synthesis Reference

Alan B. Gancy, "Process of making calcium acetate deicing agents and product." U.S. Patent US4444672, issued November, 1946.

US4444672
General References
Not Available
External Links
KEGG Drug
D00931
PubChem Compound
6116
PubChem Substance
46507985
ChemSpider
5890
ChEBI
3310
ChEMBL
CHEMBL1200800
PharmGKB
PA164746897
Drugs.com
Drugs.com Drug Page
Wikipedia
Calcium_acetate
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumV03AE04 — Calcium acetate and magnesium carbonateV03AE07 — Calcium acetate
AHFS Codes
  • 88:29.00* — Minerals
  • 40:18.19 — Phosphate-removing Agents
FDA label
Download (25.6 KB)
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceChronic Kidney Disease (CKD) / Healthy Volunteers / Test Ferric Hydroxide Adipate as Phosphate Binder in Healthy Subjects1
3CompletedPreventionHyperphosphataemia / Renal Failure1
3CompletedTreatmentChronic Kidney Disease (CKD) / Peritoneal dialysis therapy1
3CompletedTreatmentHyperphosphataemia / Renal Failure1
3Not Yet RecruitingTreatmentHyperphosphataemia1
3RecruitingTreatmentHyperphosphataemia1
3Unknown StatusTreatmentChronic Kidney Disease (CKD)1
4CompletedPreventionWe Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients1
4CompletedTreatmentArteriosclerosis / Calcinosis / Hyperparathyroidism, Secondary1
4CompletedTreatmentCardiovascular Events / Hemodialysis-dependent patients / Hyperphosphataemia1
4CompletedTreatmentChronic Kidney Disease (CKD)1
4TerminatedPreventionChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionChronic Kidney Disease (CKD)1
Not AvailableCompletedPreventionRenal Failure1
Not AvailableWithdrawnTreatmentHaemodialyzed Patients / Hyperphosphataemia1

Pharmacoeconomics

Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
  • Biotest Pharmaceuticals
  • Braintree Laboratories Inc.
  • Hawthorn Pharmaceuticals
  • Kaiser Foundation Hospital
  • Murfreesboro Pharmaceutical Nursing Supply
  • Physicians Total Care Inc.
  • Roxane Labs
  • Stason Pharmaceuticals Inc.
  • Tya Pharmaceuticals
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
Powder, for solutionTopical
TabletOral667 mg
SolutionIntravenous
LiquidIntravenous
Injection, solution, concentrateIntravenous
CapsuleOral667 mg/1
TabletOral667 mg/1
SolutionOral667 mg/5mL
InjectionIntravenous
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6576665No2001-04-032021-04-03Us
US6875445No2001-07-302021-07-30Us
US8591938No2010-02-232030-02-23Us
US8592480No2007-07-202027-07-20Us
US9089528No2007-07-202027-07-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)> 160 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility147.0 mg/mLALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 inhibitorNon-inhibitor0.9273
CYP450 2D6 inhibitorNon-inhibitor0.9462
CYP450 2C19 inhibitorNon-inhibitor0.9608
CYP450 3A4 inhibitorNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Carboxylic acids
Direct Parent
Carboxylic acids
Alternative Parents
Monocarboxylic acids and derivatives / Organic salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular Framework
Not Available
External Descriptors
calcium salt (CHEBI:3310)

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Binder
References
  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. [PubMed:2811066]
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. [PubMed:12815333]
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. [PubMed:15882308]
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. [PubMed:15954948]

Drug created on June 13, 2005 07:24 / Updated on September 25, 2018 17:45